1. Home
  2. JFU vs COCH Comparison

JFU vs COCH Comparison

Compare JFU & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

HOLD

Current Price

$3.08

Market Cap

46.7M

Sector

Finance

ML Signal

HOLD

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.71

Market Cap

49.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFU
COCH
Founded
2006
1995
Country
China
United States
Employees
N/A
47
Industry
Finance: Consumer Services
Blank Checks
Sector
Finance
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
46.7M
49.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
JFU
COCH
Price
$3.08
$0.71
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
7.2K
109.3K
Earning Date
12-09-2022
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.58
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.25
$0.36
52 Week High
$9.48
$1.89

Technical Indicators

Market Signals
Indicator
JFU
COCH
Relative Strength Index (RSI) 41.97 53.76
Support Level $2.65 $0.63
Resistance Level $4.79 $0.74
Average True Range (ATR) 0.47 0.04
MACD -0.07 0.00
Stochastic Oscillator 7.07 58.18

Price Performance

Historical Comparison
JFU
COCH

About JFU 9F Inc.

9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: